메뉴 건너뛰기




Volumn 2, Issue , 2005, Pages 0225-0235

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; ERLOTINIB; GEFITINIB; IMATINIB; METHIONINE; PACLITAXEL; THREONINE; TRASTUZUMAB; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; QUINAZOLINE DERIVATIVE;

EID: 18244371651     PISSN: 15491277     EISSN: None     Source Type: Journal    
DOI: 10.1371/journal.pmed.0020073     Document Type: Article
Times cited : (3217)

References (28)
  • 1
    • 2342471392 scopus 로고    scopus 로고
    • Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
    • Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139.
    • (2004) N Engl J Med , vol.350 , pp. 2129-2139
    • Lynch, T.J.1    Bell, D.W.2    Sordella, R.3    Gurubhagavatula, S.4    Okimoto, R.A.5
  • 2
    • 2342624080 scopus 로고    scopus 로고
    • EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy
    • Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, et al. (2004) EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304: 1497-1500.
    • (2004) Science , vol.304 , pp. 1497-1500
    • Paez, J.G.1    Janne, P.A.2    Lee, J.C.3    Tracy, S.4    Greulich, H.5
  • 3
    • 4444344330 scopus 로고    scopus 로고
    • EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib
    • Pao W, Miller V, Zakowski M, Doherty J, Politi K, et al. (2004) EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101: 13306-13311.
    • (2004) Proc Natl Acad Sci U S A , vol.101 , pp. 13306-13311
    • Pao, W.1    Miller, V.2    Zakowski, M.3    Doherty, J.4    Politi, K.5
  • 4
    • 19944426858 scopus 로고    scopus 로고
    • High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan
    • Huang SF, Liu HP, Li LH, Ku YC, Fu YN, et al. (2004) High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 10: 8195-8203.
    • (2004) Clin Cancer Res , vol.10 , pp. 8195-8203
    • Huang, S.F.1    Liu, H.P.2    Li, L.H.3    Ku, Y.C.4    Fu, Y.N.5
  • 5
    • 10844231985 scopus 로고    scopus 로고
    • Mutations of the epidermal growth factor receptor gene in lung cancer: Biological and clinical implications
    • Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, et al. (2004) Mutations of the epidermal growth factor receptor gene in lung cancer: Biological and clinical implications. Cancer Res 64: 8919-8923.
    • (2004) Cancer Res , vol.64 , pp. 8919-8923
    • Kosaka, T.1    Yatabe, Y.2    Endoh, H.3    Kuwano, H.4    Takahashi, T.5
  • 6
    • 20044364940 scopus 로고    scopus 로고
    • Clinical and biological features of epidermal growth factor receptor mutations in lung cancers
    • In press
    • Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, et al. (2004) Clinical and biological features of epidermal growth factor receptor mutations in lung cancers. J Natl Cancer Inst. In press.
    • (2004) J Natl Cancer Inst
    • Shigematsu, H.1    Lin, L.2    Takahashi, T.3    Nomura, M.4    Suzuki, M.5
  • 7
    • 15744372810 scopus 로고    scopus 로고
    • KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib
    • Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, et al. (2005) KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Medicine 2: e17.
    • (2005) PLoS Medicine , vol.2
    • Pao, W.1    Wang, T.Y.2    Riely, G.J.3    Miller, V.A.4    Pan, Q.5
  • 8
    • 13844261148 scopus 로고    scopus 로고
    • The development of imatinib as a therapeutic agent for chronic myeloid leukemia
    • Epub ahead of print
    • Deininger M, Buchdunger E, Druker BJ (2004) The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood: Epub ahead of print.
    • (2004) Blood
    • Deininger, M.1    Buchdunger, E.2    Druker, B.J.3
  • 9
    • 1342287959 scopus 로고    scopus 로고
    • High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib
    • Al-Ali HK, Heinrich MC, Lange T, Krahl R, Mueller M, et al. (2004) High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib. Hematol J 5: 55-60.
    • (2004) Hematol J , vol.5 , pp. 55-60
    • Al-Ali, H.K.1    Heinrich, M.C.2    Lange, T.3    Krahl, R.4    Mueller, M.5
  • 10
    • 0035800507 scopus 로고    scopus 로고
    • Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
    • Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, et al. (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293: 876-880.
    • (2001) Science , vol.293 , pp. 876-880
    • Gorre, M.E.1    Mohammed, M.2    Ellwood, K.3    Hsu, N.4    Paquette, R.5
  • 11
    • 0001686739 scopus 로고    scopus 로고
    • Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
    • Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, et al. (2002) Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2: 117-125.
    • (2002) Cancer Cell , vol.2 , pp. 117-125
    • Shah, N.P.1    Nicoll, J.M.2    Nagar, B.3    Gorre, M.E.4    Paquette, R.L.5
  • 12
    • 4644368478 scopus 로고    scopus 로고
    • Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: Implications for CML
    • O'Hare T, Pollock R, Stoffregen EP, Keats JA, Abdullah OM, et al. (2004) Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: Implications for CML. Blood 104: 2532-2539.
    • (2004) Blood , vol.104 , pp. 2532-2539
    • O'Hare, T.1    Pollock, R.2    Stoffregen, E.P.3    Keats, J.A.4    Abdullah, O.M.5
  • 13
    • 3142676436 scopus 로고    scopus 로고
    • Overriding imatinib resistance with a novel ABL kinase inhibitor
    • Shah NP, Tran C, Lee FY, Chen P, Norris D, et al. (2004) Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305: 399-401.
    • (2004) Science , vol.305 , pp. 399-401
    • Shah, N.P.1    Tran, C.2    Lee, F.Y.3    Chen, P.4    Norris, D.5
  • 14
    • 9244222261 scopus 로고    scopus 로고
    • Targeted cancer therapy
    • Sawyers C (2004) Targeted cancer therapy. Nature 432: 294-297.
    • (2004) Nature , vol.432 , pp. 294-297
    • Sawyers, C.1
  • 15
    • 20844448396 scopus 로고    scopus 로고
    • A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient
    • Tamborini E, Bonadiman L, Greco A, Albertini V, Negri T, et al. (2004) A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology 127: 294-299.
    • (2004) Gastroenterology , vol.127 , pp. 294-299
    • Tamborini, E.1    Bonadiman, L.2    Greco, A.3    Albertini, V.4    Negri, T.5
  • 16
    • 0344987881 scopus 로고    scopus 로고
    • A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome
    • Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, et al. (2003) A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348: 1201-1214.
    • (2003) N Engl J Med , vol.348 , pp. 1201-1214
    • Cools, J.1    DeAngelo, D.J.2    Gotlib, J.3    Stover, E.H.4    Legare, R.D.5
  • 17
    • 0000940657 scopus 로고    scopus 로고
    • Randomized phase II trial of trastuzumab (tras) plus either weekly docetaxel (doc) or paclitaxel (pac) in previously untreated advanced non-small cell lung cancer (NSCLC)
    • Krug LM, Miller VA, Crapanzano J, Ng KK, Pizzo B, et al. (2001) Randomized phase II trial of trastuzumab (tras) plus either weekly docetaxel (doc) or paclitaxel (pac) in previously untreated advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 20: 1328.
    • (2001) Proc Am Soc Clin Oncol , vol.20 , pp. 1328
    • Krug, L.M.1    Miller, V.A.2    Crapanzano, J.3    Ng, K.K.4    Pizzo, B.5
  • 18
    • 4143066760 scopus 로고    scopus 로고
    • Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways
    • Sordella R, Bell DW, Haber DA, Settleman J (2004) Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305: 1163-1167.
    • (2004) Science , vol.305 , pp. 1163-1167
    • Sordella, R.1    Bell, D.W.2    Haber, D.A.3    Settleman, J.4
  • 19
    • 5644293135 scopus 로고    scopus 로고
    • Gefitinib induces apoptosis in the EGFRL858R non-small cell lung cancer cell line H3255
    • Tracy S, Mukohara T, Hansen M, Meyerson M, Johnson BE, et al. (2004) Gefitinib induces apoptosis in the EGFRL858R non-small cell lung cancer cell line H3255. Cancer Res 64: 7241-7244.
    • (2004) Cancer Res , vol.64 , pp. 7241-7244
    • Tracy, S.1    Mukohara, T.2    Hansen, M.3    Meyerson, M.4    Johnson, B.E.5
  • 21
    • 2642558897 scopus 로고    scopus 로고
    • Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors
    • Blencke S, Zech B, Engkvist O, Greff Z, Orfi L, et al. (2004) Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors. Chem Biol 11: 691-701.
    • (2004) Chem Biol , vol.11 , pp. 691-701
    • Blencke, S.1    Zech, B.2    Engkvist, O.3    Greff, Z.4    Orfi, L.5
  • 22
    • 0037674323 scopus 로고    scopus 로고
    • Mutation of threonine 766 in the epidermal growth factor receptor reveals a hotspot for resistance formation against selective tyrosine kinase inhibitors
    • Blencke S, Ullrich A, Daub H (2003) Mutation of threonine 766 in the epidermal growth factor receptor reveals a hotspot for resistance formation against selective tyrosine kinase inhibitors. J Biol Chem 278: 15435-15440.
    • (2003) J Biol Chem , vol.278 , pp. 15435-15440
    • Blencke, S.1    Ullrich, A.2    Daub, H.3
  • 23
    • 0038514851 scopus 로고    scopus 로고
    • Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique
    • Kreuzer KA, Le Coutre P, Landt O, Na IK, Schwarz M, et al. (2003) Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique. Ann Hematol 82: 284-289.
    • (2003) Ann Hematol , vol.82 , pp. 284-289
    • Kreuzer, K.A.1    Le Coutre, P.2    Landt, O.3    Na, I.K.4    Schwarz, M.5
  • 24
    • 0141599428 scopus 로고    scopus 로고
    • Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor
    • Stamos J, Sliwkowski MX, Eigenbrot C (2002) Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem 277: 46265-46272.
    • (2002) J Biol Chem , vol.277 , pp. 46265-46272
    • Stamos, J.1    Sliwkowski, M.X.2    Eigenbrot, C.3
  • 25
    • 10444280878 scopus 로고    scopus 로고
    • Strategies to overcome resistance to targeted protein kinase inhibitors
    • Daub H, Specht K, Ullrich A (2004) Strategies to overcome resistance to targeted protein kinase inhibitors. Nat Rev Cancer 3: 1001-1010.
    • (2004) Nat Rev Cancer , vol.3 , pp. 1001-1010
    • Daub, H.1    Specht, K.2    Ullrich, A.3
  • 26
    • 4644289313 scopus 로고    scopus 로고
    • A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): Relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells
    • Wood ER, Truesdale AT, McDonald OB, Yuan D, Hassell A, et al. (2004) A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): Relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 64: 6652-6659.
    • (2004) Cancer Res , vol.64 , pp. 6652-6659
    • Wood, E.R.1    Truesdale, A.T.2    McDonald, O.B.3    Yuan, D.4    Hassell, A.5
  • 27
    • 20844460619 scopus 로고    scopus 로고
    • A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors
    • Chen LL, Trent JC, Wu EF, Fuller GN, Ramdas L, et al. (2004) A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res 64: 5913-5919.
    • (2004) Cancer Res , vol.64 , pp. 5913-5919
    • Chen, L.L.1    Trent, J.C.2    Wu, E.F.3    Fuller, G.N.4    Ramdas, L.5
  • 28
    • 0036014978 scopus 로고    scopus 로고
    • Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia
    • Gorre ME, Sawyers CL (2002) Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia. Curr Opin Hematol 9: 303-307.
    • (2002) Curr Opin Hematol , vol.9 , pp. 303-307
    • Gorre, M.E.1    Sawyers, C.L.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.